Do analysts rate AGMB or CTOR?

AgomAb Therapeutics currently has a consensus target price of $37.50, suggesting a potential upside of 331.53%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe AgomAb Therapeutics is more favorable than Citius Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AgomAb Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Citius Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, AGMB or CTOR?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A -$70.77M N/A N/A Citius Oncology N/A N/A -$24.76M -$0.47 N/A

Is AGMB or CTOR more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets AgomAb Therapeutics N/A N/A N/A Citius Oncology N/A -102.98% -43.49%

Does the media refer more to AGMB or CTOR?

In the previous week, AgomAb Therapeutics had 7 more articles in the media than Citius Oncology. MarketBeat recorded 10 mentions for AgomAb Therapeutics and 3 mentions for Citius Oncology. AgomAb Therapeutics' average media sentiment score of 1.17 beat Citius Oncology's score of 0.94 indicating that AgomAb Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Citius Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend BNTC or CTOR?

Benitec Biopharma currently has a consensus price target of $24.00, indicating a potential upside of 189.51%. Given Benitec Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Benitec Biopharma is more favorable than Citius Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Benitec Biopharma 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.60 Citius Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, BNTC or CTOR?

Benitec Biopharma is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Benitec Biopharma N/A N/A -$45.55M -$0.98 N/A Citius Oncology N/A N/A -$24.76M -$0.47 N/A

Is BNTC or CTOR more profitable?

Benitec Biopharma's return on equity of -28.41% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Benitec Biopharma N/A -28.41% -27.76% Citius Oncology N/A -102.98% -43.49%

Does the media refer more to BNTC or CTOR?

In the previous week, Benitec Biopharma had 1 more articles in the media than Citius Oncology. MarketBeat recorded 4 mentions for Benitec Biopharma and 3 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.94 beat Benitec Biopharma's score of 0.56 indicating that Citius Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Benitec Biopharma 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Citius Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate CTOR or ELYM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, CTOR or ELYM?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Citius Oncology N/A N/A -$24.76M -$0.47 N/A Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A

Is CTOR or ELYM more profitable?

Eliem Therapeutics' return on equity of -47.03% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Citius Oncology N/A -102.98% -43.49% Eliem Therapeutics N/A -47.03% -45.97%

Do analysts prefer CTOR or INDP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, CTOR or INDP?

Citius Oncology is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Citius Oncology N/A N/A -$24.76M -$0.47 N/A Indaptus Therapeutics N/A N/A -$20.85M -$6.33 N/A

Is CTOR or INDP more profitable?

Citius Oncology's return on equity of -102.98% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Citius Oncology N/A -102.98% -43.49% Indaptus Therapeutics N/A -302.89% -203.49%

Do analysts recommend CTOR or PRLD?

Prelude Therapeutics has a consensus target price of $8.75, indicating a potential upside of 170.90%. Given Prelude Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Prelude Therapeutics is more favorable than Citius Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Prelude Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Is CTOR or PRLD more profitable?

Prelude Therapeutics' return on equity of -75.35% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Citius Oncology N/A -102.98% -43.49% Prelude Therapeutics N/A -75.35% -44.39%

Does the media favor CTOR or PRLD?

In the previous week, Prelude Therapeutics had 3 more articles in the media than Citius Oncology. MarketBeat recorded 6 mentions for Prelude Therapeutics and 3 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.94 beat Prelude Therapeutics' score of -0.14 indicating that Citius Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prelude Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Citius Oncology (CTOR) Competitors

$0.75 -0.04 (-4.80%)

Closing price 04:00 PM Eastern

Extended Trading

$0.76 +0.01 (+1.88%)

As of 06:10 PM Eastern

Compare

CTOR vs. AGMB, BNTC, ELYM, INDP, and PRLD

Should you buy Citius Oncology stock or one of its competitors? Citius Oncology's main competitors and comparable companies include AgomAb Therapeutics (AGMB), Benitec Biopharma (BNTC), Eliem Therapeutics (ELYM), Indaptus Therapeutics (INDP), and Prelude Therapeutics (PRLD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Citius Oncology compare to AgomAb Therapeutics?

AgomAb Therapeutics (NASDAQ:AGMB) and Citius Oncology (NASDAQ:CTOR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

AgomAb Therapeutics currently has a consensus target price of $37.50, suggesting a potential upside of 331.53%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe AgomAb Therapeutics is more favorable than Citius Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A

AgomAb Therapeutics' return on equity of 0.00% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Citius Oncology	N/A	-102.98%	-43.49%

70.5% of Citius Oncology shares are held by institutional investors. 9.8% of Citius Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, AgomAb Therapeutics had 7 more articles in the media than Citius Oncology. MarketBeat recorded 10 mentions for AgomAb Therapeutics and 3 mentions for Citius Oncology. AgomAb Therapeutics' average media sentiment score of 1.17 beat Citius Oncology's score of 0.94 indicating that AgomAb Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Citius Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

AgomAb Therapeutics beats Citius Oncology on 7 of the 10 factors compared between the two stocks.

How does Citius Oncology compare to Benitec Biopharma?

Benitec Biopharma (NASDAQ:BNTC) and Citius Oncology (NASDAQ:CTOR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

Benitec Biopharma's return on equity of -28.41% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-28.41%	-27.76%
Citius Oncology	N/A	-102.98%	-43.49%

In the previous week, Benitec Biopharma had 1 more articles in the media than Citius Oncology. MarketBeat recorded 4 mentions for Benitec Biopharma and 3 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.94 beat Benitec Biopharma's score of 0.56 indicating that Citius Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Benitec Biopharma	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Citius Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Benitec Biopharma has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.39, suggesting that its stock price is 239% more volatile than the broader market.

Benitec Biopharma is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	N/A	N/A	-$45.55M	-$0.98	N/A
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A

Benitec Biopharma currently has a consensus price target of $24.00, indicating a potential upside of 189.51%. Given Benitec Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Benitec Biopharma is more favorable than Citius Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

52.2% of Benitec Biopharma shares are owned by institutional investors. Comparatively, 70.5% of Citius Oncology shares are owned by institutional investors. 4.8% of Benitec Biopharma shares are owned by company insiders. Comparatively, 9.8% of Citius Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Benitec Biopharma and Citius Oncology tied by winning 6 of the 12 factors compared between the two stocks.

How does Citius Oncology compare to Eliem Therapeutics?

Citius Oncology (NASDAQ:CTOR) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 9.8% of Citius Oncology shares are owned by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Eliem Therapeutics' return on equity of -47.03% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-102.98%	-43.49%
Eliem Therapeutics	N/A	-47.03%	-45.97%

Citius Oncology has a beta of 3.39, meaning that its share price is 239% more volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, meaning that its share price is 139% less volatile than the broader market.

In the previous week, Citius Oncology had 3 more articles in the media than Eliem Therapeutics. MarketBeat recorded 3 mentions for Citius Oncology and 0 mentions for Eliem Therapeutics. Citius Oncology's average media sentiment score of 0.94 beat Eliem Therapeutics' score of 0.00 indicating that Citius Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Citius Oncology	Positive
Eliem Therapeutics	Neutral

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

Summary

Citius Oncology beats Eliem Therapeutics on 9 of the 10 factors compared between the two stocks.

How does Citius Oncology compare to Indaptus Therapeutics?

Citius Oncology (NASDAQ:CTOR) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Citius Oncology is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$6.33	N/A

70.5% of Citius Oncology shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 9.8% of Citius Oncology shares are held by insiders. Comparatively, 9.9% of Indaptus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Citius Oncology's return on equity of -102.98% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-102.98%	-43.49%
Indaptus Therapeutics	N/A	-302.89%	-203.49%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Citius Oncology had 2 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 3 mentions for Citius Oncology and 1 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.79 beat Citius Oncology's score of 0.94 indicating that Indaptus Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Citius Oncology	Positive
Indaptus Therapeutics	Very Positive

Citius Oncology has a beta of 3.39, indicating that its share price is 239% more volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

Summary

Citius Oncology beats Indaptus Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Citius Oncology compare to Prelude Therapeutics?

Citius Oncology (NASDAQ:CTOR) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

Prelude Therapeutics has a consensus target price of $8.75, indicating a potential upside of 170.90%. Given Prelude Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Prelude Therapeutics is more favorable than Citius Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Prelude Therapeutics' return on equity of -75.35% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-102.98%	-43.49%
Prelude Therapeutics	N/A	-75.35%	-44.39%

In the previous week, Prelude Therapeutics had 3 more articles in the media than Citius Oncology. MarketBeat recorded 6 mentions for Prelude Therapeutics and 3 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.94 beat Prelude Therapeutics' score of -0.14 indicating that Citius Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Citius Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prelude Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Citius Oncology has higher earnings, but lower revenue than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
Prelude Therapeutics	$12.14M	21.23	-$99.50M	-$0.73	N/A

70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 9.8% of Citius Oncology shares are owned by company insiders. Comparatively, 49.2% of Prelude Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Citius Oncology has a beta of 3.39, indicating that its stock price is 239% more volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Summary

Prelude Therapeutics beats Citius Oncology on 8 of the 13 factors compared between the two stocks.

Get Citius Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTOR vs. The Competition

Export

Metric	Citius Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$69.36M	$3.96B	$7.43B	$12.93B
Dividend Yield	N/A	3.65%	2.52%	19.59%
P/E Ratio	-1.59	12.51	274.96	25.39
Price / Sales	9.76	1,202.47	608.73	90.53
Price / Cash	N/A	119.79	76.68	52.75
Price / Book	1.38	15.79	10.32	6.02
Net Income	-$24.76M	-$22.69M	$3.49B	$380.68M
7 Day Performance	-10.66%	-4.31%	-2.54%	-3.01%
1 Month Performance	-12.85%	-11.49%	-6.87%	-5.59%
1 Year Performance	-56.63%	4.54%	1.81%	-5.23%

Citius Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTOR Citius Oncology	1.2132 of 5 stars	$0.75 -4.8%	N/A	-53.9%	$69.36M	$7.11M	N/A	285	News Coverage Short Interest Decrease Gap Down
AGMB AgomAb Therapeutics	3.6767 of 5 stars	$8.84 +0.0%	$37.50 +324.0%	N/A	$320.88M	N/A	N/A	62
BNTC Benitec Biopharma	2.6329 of 5 stars	$9.12 +1.3%	$24.00 +163.2%	-45.0%	$319.43M	N/A	N/A	24
ELYM Eliem Therapeutics	N/A	$10.68 -3.3%	N/A	+415.5%	$317.75M	N/A	N/A	9
INDP Indaptus Therapeutics	1.0389 of 5 stars	$2.36 -9.0%	N/A	-46.9%	$314.45M	N/A	N/A	5	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTOR) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Citius Oncology (CTOR) Competitors

CTOR vs. AGMB, BNTC, ELYM, INDP, and PRLD

How does Citius Oncology compare to AgomAb Therapeutics?

Summary

How does Citius Oncology compare to Benitec Biopharma?

Summary

How does Citius Oncology compare to Eliem Therapeutics?

Summary

How does Citius Oncology compare to Indaptus Therapeutics?

Summary

How does Citius Oncology compare to Prelude Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTOR vs. The Competition

Citius Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Citius Oncology (CTOR) Competitors

CTOR vs. AGMB, BNTC, ELYM, INDP, and PRLD

How does Citius Oncology compare to AgomAb Therapeutics?

Do analysts rate AGMB or CTOR?

Which has preferable earnings & valuation, AGMB or CTOR?

Is AGMB or CTOR more profitable?

Do insiders & institutionals have more ownership in AGMB or CTOR?

Does the media refer more to AGMB or CTOR?

Summary

How does Citius Oncology compare to Benitec Biopharma?

Is BNTC or CTOR more profitable?

Does the media refer more to BNTC or CTOR?

Which has more risk & volatility, BNTC or CTOR?

Which has preferable valuation and earnings, BNTC or CTOR?

Do analysts recommend BNTC or CTOR?

Do insiders and institutionals have more ownership in BNTC or CTOR?

Summary

How does Citius Oncology compare to Eliem Therapeutics?

Do analysts rate CTOR or ELYM?

Do insiders & institutionals have more ownership in CTOR or ELYM?

Is CTOR or ELYM more profitable?

Which has more risk & volatility, CTOR or ELYM?

Does the media favor CTOR or ELYM?

Which has preferable earnings and valuation, CTOR or ELYM?

Summary

How does Citius Oncology compare to Indaptus Therapeutics?

Which has better earnings and valuation, CTOR or INDP?

Do institutionals & insiders believe in CTOR or INDP?

Is CTOR or INDP more profitable?

Do analysts prefer CTOR or INDP?

Does the media favor CTOR or INDP?

Which has more volatility & risk, CTOR or INDP?

Summary

How does Citius Oncology compare to Prelude Therapeutics?

Do analysts recommend CTOR or PRLD?

Is CTOR or PRLD more profitable?

Does the media favor CTOR or PRLD?

Which has better valuation & earnings, CTOR or PRLD?

Do institutionals and insiders believe in CTOR or PRLD?

Which has more risk & volatility, CTOR or PRLD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTOR vs. The Competition

Citius Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools